Recruiting
A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome
NCT07710196· Phase 3· Nacuity Pharmaceuticals, Inc.· Source
Recruiting
A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
NCT07734064· Phase 1· Astellas Institute for Regenerative Medicine· Source
Recruiting
Study of ALK-001 on the Progression of Stargardt Disease
NCT07419334· Phase 3· Alkeus Pharmaceuticals, Inc.· Source
Recruiting
A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
NCT07408232· Phase 1/2· Octant, Inc.· Source
Recruiting
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
NCT07425574· Astellas Pharma Global Development, Inc.· Source
Recruiting
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
NCT07230834· Phase 1· Regeneron Pharmaceuticals· Source
Recruiting
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
NCT07392255· Phase 1/2· Complement Therapeutics· Source
Recruiting
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
NCT07215234· Phase 1/2· Sanofi· Source
Recruiting
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
NCT07161544· Phase 1/2· AAVantgarde Bio Srl· Source
Recruiting
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
NCT07185256· Phase 1/2· Opus Genetics, Inc· Source
Active, not recruiting
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
NCT07174726· Phase 2· Beacon Therapeutics· Source
Recruiting
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07160179· Phase 1/2· AbbVie· Source
Recruiting
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
NCT07144137· Complement Therapeutics· Source
Active, not recruiting
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
NCT06852963· Phase 1/2· PYC Therapeutics· Source
Recruiting
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
NCT06924021· University of Wisconsin, Madison· Source
Recruiting
A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)
NCT06789445· Phase 1/2· BlueRock Therapeutics· Source
Recruiting
A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)
NCT06942572· Phase 1/2· Splice Bio· Source
Active, not recruiting
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06769048· Phase 2· Boehringer Ingelheim· Source
Active, not recruiting
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06627179· Phase 2· Laboratoires Thea· Source
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816· Phase 3· Annexon, Inc.· Source
Active, not recruiting
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT06388200· Phase 3· Ocugen· Source
Active, not recruiting
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
NCT06467344· Phase 1/2· Ascidian Therapeutics, Inc· Source
Active, not recruiting
An Observational Study in Children and Adults With Stargardt Disease
NCT06591806· AAVantgarde Bio Srl· Source
Recruiting
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
NCT06435000· Splice Bio· Source
Active, not recruiting
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
NCT04850118· Phase 2/3· Beacon Therapeutics· Source
Enrolling by invitation
A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
NCT06275620· Phase 2· Beacon Therapeutics· Source
Active, not recruiting
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
NCT06018558· Phase 1/2· Ocugen· Source
Active, not recruiting
Oral N-acetylcysteine for Retinitis Pigmentosa
NCT05537220· Phase 3· Johns Hopkins University· Source
Active, not recruiting
A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
NCT05956626· Phase 2/3· Ocugen· Source
Recruiting
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants
NCT05589714· Jaeb Center for Health Research· Source
Active, not recruiting
Promising ROd-cone DYstrophy Gene therapY
NCT05748873· Phase 1/2· SparingVision· Source
Active, not recruiting
Natural History of PRPF31 Mutation-Associated Retinal Dystrophy
NCT05573984· PYC Therapeutics· Source
Active, not recruiting
An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
NCT05300724· Genentech, Inc.· Source
Active, not recruiting
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
NCT06333249· Phase 2· Beacon Therapeutics· Source
Active, not recruiting
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
NCT04517149· Phase 1/2· 4D Molecular Therapeutics· Source
Active, not recruiting
Rate of Progression in EYS Related Retinal Degeneration
NCT04127006· Jaeb Center for Health Research· Source
Active, not recruiting
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
NCT04123626· Phase 1/2· ProQR Therapeutics· Source
Recruiting
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
NCT03178149· Phase 1· Astellas Institute for Regenerative Medicine· Source
Active, not recruiting
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
NCT03316560· Phase 1/2· Beacon Therapeutics· Source
Active, not recruiting
Rate of Progression in USH2A-related Retinal Degeneration
NCT03146078· Jaeb Center for Health Research· Source